Cost effectiveness of insulin glargine plus oral antidiabetes drugs compared with premixed insulin alone in patients with type 2 diabetes mellitus in Canada

Applied Health Economics and Health Policy

Volumn 8, Issue 4, 2010, Pages 267-280

  Tunis, Sandra L ^a   Sauriol, Luc ^b   Minshall, Michael E ^a  

^a IQVIA   (United States)

^b Health Economic and Health Outcomes   (Canada)

Author keywords

cost utility; glimepiride; insulin glargine; insulin suspension isophaneinsulin; metformin; therapeutic use; treatment; type 2 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; HEMOGLOBIN A1C; INSULIN GLARGINE;

ADULT; ARTICLE; CANADA; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG EFFECT; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; LIFE EXPECTANCY; LIFESPAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY ADJUSTED LIFE YEAR; TREATMENT OUTCOME;

CANADA; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; SULFONYLUREA COMPOUNDS;

EID: 77954092776     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.2165/11535380-000000000-00000     Document Type: Article

References (48)

1. Canadian Diabetes Association. The prevalence and cost of diabetes [online]. Available from URL: http://www. diabetes.ca/about-diabetes/what/ prevalence/[Accessed 2009 Dec 1]
2. Public Health Agency of Canada. Diabetes [online]. Avail-able from URL: http://www.phac-aspc.gc.ca/ccdpc-cpcmc/diabetes-diabete/english/pubs/ ndfs-fnrd07-eng.html [Accessed 2008 Jun 1]
3. Canadian Optimal Medication Prescribing and Utilization Services. An economic evaluation of insulin analogues for the treatment of patients with type 1 and type 2 diabetes mellitus in Canada. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health (CADTH) 2008 [online]. Available from URL: http://www.cadth.ca/index.php/en/compus/insulin-analogs/reports [Accessed 2009 Sep]
4. Canadian Optimal Medication Prescribing and Utilization Services. Cost-effectiveness of blood glucose test strips in the management of adult patients with diabetes mellitus. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health (CADTH) 2009 [online]. Available from URL: http://www.cadth.ca/index.php/en/compus/insulin-analogs/reports [Accessed 2009 Sep]
5. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS 33) [published erratum appears in Lancet 1999; 354 (9178): 602]. Lancet 1998; 352 (9131): 837-853
6. Canadian Diabetes Association Clinical Practice Guide-lines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008; 32 (1 Suppl.): 1-201S
7. Henderson JN, Allen KV, Deary IJ, et al. Hypoglycae-mia in insulin-treated type 2 diabetes: frequency, symptoms and impaired awareness. Diabet Med 2003; 20 (12): 1016-1021
8. Janka HU, Plewe G, Riddle MC, et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005; 28: 254-259
9. Palmer AJ, Roze S, Valentine WJ, et al. The CORE diabetes model: projecting long term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision making. Curr Med Res Opin 2004; 20 (1 Suppl.): 5-26S
10. Palmer AJ, Roze S, Valentine WJ, et al. Validation of the CORE diabetes model against epidemiological and clinical studies. Curr Med Res Opin 2004; 20 (1 Suppl.): 27S-40S
11. D'Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J 2000; 139 (2 Pt 1): 272-281
12. American Diabetes Association Consensus Panel. Guide-lines for computer modeling of diabetes and its complications. Diabetes Care 2004; 27 (9): 2262-2265
13. Centers for Disease Control and Prevention, National Cen-ter for Health Statistics. NHANES 1999-2000 dataset: diabetes survey. Hyattsville (MD): CDC, 2002 [online]. Available from URL: http://www.cdc.gov/nchs/data/nhanes/spq-di. pdf [Accessed 2009 Jan 1]
14. O'Reilly D, Hopkins R, Blackhouse G, et al. Development of an Ontario Diabetes Economic Model (ODEM) and application to a multidisciplinary primary care diabetes management program. Hamilton (ON): Program for Assessment of Technology in Health (PATH), 2006 [online]. Available from URL: http://www.path-hta.ca/diabetes.pdf [Accessed 2009 Jan 1]
15. Statistics Canada. Visible minority population, by age group. In: 2001 census of Canada. Ottawa (ON): Statistics Canada, 2007
16. Harris MI, Cowie CC, Stern MP. Diabetes in America. 2nd ed. [NIH publication no. 95-1468]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases, 1995 [online]. Available from URL: http://diabetes. niddk.nih.gov/dm/pubs/america/contents.htm [Accessed 2009 Feb 1]
17. Harris MI. Health care and health status and outcomes for patients with type 2 diabetes. Diabetes Care 2000; 23 (6): 754-758
18. Moss SE, Klein R, Klein BE. The prevalence and incidence of lower extremity amputation in a diabetic population. Arch Inter Med 1992; 152 (3): 610-616
19. Brandle M, Zhou H, Smith BR et al. The direct medical cost of type 2 diabetes. Diabetes Care 2003; 26 (8): 2300-2304
20. Turner RC, Cull CA, Frighi V, UKPDS Study Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281 (21): 2005-2012
21. Statistics Canada. Life tables, Canada, provinces and terri-tories: 2000-2002. Ottawa (ON): Statistics Canada, 2006 [online; subscriber only]. Available from URL: http://dsp-psd.pwgsc.gc.ca/Collection/Statcan [Accessed 2009 Dec 1]
22. Royal Bank of Canada. Inflation calculator [online]. Avail-able from URL: http://www.bankofcanada.ca/en/rates/inflation-calc.html [Accessed 2009 Jun 1]
23. Sullivan PW, Ghush V. Preference-based EQ-5D index scores for chronic conditions in the United States. Med Decis Making 2006; 26 (4): 410-420
24. Alberta Health and Wellness. Health costing in Alberta: 2006 annual report. Edmonton (AB): Alberta Health and Wellness, 2008
25. Caro J, Migliaccio-Walle K, Ishak KJ, et al. The morbidity and mortality following a diagnosis of peripheral arterial disease: long-term follow-up of a large database [abstract]. BMC Cardiovas Disord 2005; 5: 14
26. Hart HE, Redekop WK, Berg M, et al. Factors that pre-dicted change in health-related quality of life were identified in a cohort of diabetes mellitus type 1 patients. J Clin Epidemiol 2005; 58 (11): 1158-1164
27. Manns B, Johnson JA, Taub K, et al. Quality of life in patients with end-stage renal disease over time: the impact of dialysis modality and other important determinants [working paper report no. 02-05]. Edmonton (AB): Institute of Pharmaco-Economics, 2002
28. Manns B, Tonelli M, Shrive F, et al. Sevelamer in patients with end-stage renal disease: a systematic review and economic evaluation. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2006 [online]. Available from URL: http://www.cadth.ca/media/pdf/HTA-349-se velamer-tr-e.pdf [Accessed 2009 Jan 1]
29. Kiberd BA, Larson T. Estimating the benefits of solitary pancreas transplantation in nouremic patients with type 1 diabetes: a theoretical analysis. Transplantation 2000; 70 (7): 1121-1127
30. O'Brien JA, Patrick AR, Caro JJ. Cost of managing com-plications resulting from type 2 diabetes mellitus in Canada. BMC Health Services Research 2003; 3 (1): 7
31. Ray JA, Valentine W, Secnik K, et al. Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and Spain. Cur Med Res Opin 2005; 21 (10): 1617-1629
32. Redekop WK, Stolk EA, Kok E, et al. Diabetic foot ulcers and amputations: estimates of health utility for use in cost-effectiveness analyses of new treatments. Diabetes Metab 2004; 30 (6): 549-556
33. Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (ULPDS 62). Med Decis Making 2002; 22 (4): 340-349
34. Calculating the US population-based EQ-5D index score. Rockville (MD): Agency for Healthcare Research and Quality 2005 [online]. Available from URL: http://www.ahrq.gov/rice/EQ5Dscore.htm [Accessed 2007 Oct 10]
35. Statistics Canada. Summary tables: diabetes, by sex, pro-vinces and territories [online]. Available from URL: http://www40.statcan.ca [Accessed 2009 Sep 1]
36. Ontario Drug Benefit Plan 2008 [online]. Available from URL: http://www.health.gov.on.ca/english/provi ders/program/drugs/edition-41.html [Accessed 2008 Oct 1]
37. Ontario Ministry of Health and Long-Term Care. Form-ulary search [online]. Available from URL: https://www.healthinfo.moh.gov.on.ca/formulary/ index.jsp [Accessed 2008 Sep 1]
38. Regie de l'assurance maladie du Quebec. Liste des medica-ments. Quebec (QC): Bibliotheque et Archives Nationales du Quebec, 2008 Jun
39. Canadian Agency for Drugs and Technologies in Health (CADTH). Guidelines for the economic evaluation of health technologies: Canada. 3rd ed. Ottawa (ON): CADTH Publications 2006 [online]. Available from URL: http://www.cadth.ca/ media/pdf/186-EconomicGuidelines-e. pdf [Accessed 2009 Jan 1]
40. ISPOR Global Health Care Systems Road Map. Re-imbursement processes around the world [online]. Available from URL: http://www.ispor.org/HTARoadMaps [Accessed 2009 Jun 1]
41. National Institute for Health and Clinical Excellence (NICE). Guidance on the use of long-acting insulin analogues for the treatment of diabetes: insulin glargine [technology appraisal guidance no. 53]. London: NICE 2002 Jan 12 [online]. Available from URL: http://www.nice. org.uk/nicemedia/pdf/53-Insulin- analogues-full-guidance. pdf [Accessed 2009 Sep 1]
42. Currie CJ, Morrissey M, Peters JR, et al. The impact of health-related quality of life (EQ-5 index) in people with type 1 diabetes who experience severe hypoglycaemia [abstract]. Diabetologia 2005; 48: A292-3
43. Halpern EF, Weinstein MC, Hunink MG, et al. Represent-ing both first-and second-order uncertainties by Monte Carlo simulation for groups of patients. Med Decis Making 2000; 20: 314-322
44. Briggs AH, Gray AM. Handling uncertainty in economic evaluations of healthcare interventions. BMJ 1999; 319 (7210): 635-638
45. Fenwick E, Briggs A. Cost-effectiveness acceptability curves in the dock: case not proven? Med Decis Making 2007; 27 (2): 93-95
46. Currie CJ, Morgan CL, Poole CD, et al. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin 2006; 22 (8): 1523-1534
47. Grima DT, Thompson MF, Sauriol L. Modelling cost effec-tiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada. Pharmacoeconomics 2007; 25 (3): 253-266
48. Pelletier EM, Smith P, Boye KS, et al. Direct medical costs for type 2 diabetes mellitus complications in the US commercial payer setting: a resource for economic research. Appl Health Econ Health Policy 2008; 6 (2): 103-112